ban on semaglutide Regulator acts to close loophole enabling Australian pharmacists to make copycat Ozempic drug Compounded Semaglutide & Tirzepatide 2025:

Advanced triple agonist research peptide targeting GLP-1, GIP, and Glucagon receptors for metabolic study.

By supporting digestive function and gut balance, this formula aids in nutrient absorption, helping your body naturally aid burn excess fat

GLP-1 medications are increasingly prescribed off-label for weight management in non-diabetic adults

(Click to view third-party Certificate of Analysis) The compound is produced under controlled manufacturing standards and undergoes analytical testing to verify purity and identity.This material is supplied strictly for laboratory research and analytical use by qualified professionals

So, which patients should clinicians actually be screening

Early clinical trials have shown significant weight loss results, even greater than current GLP-1 drugs like semaglutide (found in Ozempic and Wegovy).